Back to articles
Comparative guide · 7 min read

TUDCA vs NAC for liver — bile acids, antioxidants, and what each actually does

Updated 2026-05-15 · Reviewed by SupplementScore editors · No sponsorships

TUDCA and NAC are the two most-discussed "liver" supplements in the lifter and biohacker corners of the internet, and they answer very different questions. TUDCA (tauroursodeoxycholic acid) is a bile acid and an endoplasmic-reticulum-stress chaperone — it has a real clinical role in cholestatic liver disease. NAC (N-acetylcysteine) is a glutathione precursor with a 50-year track record as the antidote to acetaminophen toxicity and emerging evidence in NAFLD/MASLD. They are not interchangeable.

Quick verdict

GoalBetter choiceWhy
Cholestasis / bile flow problems / elevated ALPTUDCA (or UDCA)Bile-acid pharmacology — UDCA is the on-label drug; TUDCA is the conjugated supplement form with similar but less-studied data.
NAFLD / MASLD with elevated ALTNAC (mild edge)Several small RCTs show NAC reduces transaminases in NAFLD; TUDCA trials are smaller and earlier-stage.
Acetaminophen toxicity prophylaxis / known exposureNACNAC is the established antidote (IV in hospital, oral over-the-counter has supportive but weaker data for casual use).
Oral-anabolic-steroid liver protectionTUDCA (with massive caveats)The most common use case among lifters; bile-flow rationale plausible; the better answer is not using oral 17-α-alkylated steroids.
Antioxidant / glutathione repletion broadlyNACNAC raises hepatic glutathione; TUDCA does not.
Cost per day at typical doseNACNAC 600–1200 mg/day runs <$0.30; TUDCA 500–1000 mg/day runs $1–3.

How they actually work

TUDCA — the bile-acid chaperone

TUDCA is the taurine-conjugated form of ursodeoxycholic acid (UDCA). UDCA is the licensed drug used in primary biliary cholangitis (PBC), where decades of data show biochemical and survival benefits. The mechanism stack is layered: TUDCA shifts the bile-acid pool toward less-cytotoxic species, reduces ER stress via chaperone activity, and reduces hepatocyte apoptosis under cholestatic stress. Outside cholestasis, the supplement-grade evidence is much thinner — animal studies, mechanism papers, and small open-label series in NAFLD or ALS rather than large pivotal trials.

NAC — the glutathione precursor

NAC delivers cysteine, the rate-limiting amino acid for glutathione synthesis. Glutathione is the dominant intracellular antioxidant and conjugates the toxic NAPQI metabolite of acetaminophen in the liver. IV NAC remains the standard antidote for acetaminophen overdose with strong supporting data — early treatment essentially eliminates fatal hepatotoxicity. Beyond that emergency niche, oral NAC at 600–1200 mg/day has modest but consistent effects in NAFLD (transaminase reductions), PCOS-related metabolic markers, and some psychiatric endpoints.

NAFLD / MASLD — small wins, neither curative

For NAFLD/MASLD without significant fibrosis, NAC has the slightly cleaner dataset: a handful of small RCTs show ALT reductions and modest histologic improvement at 600–1200 mg/day for 3–6 months. TUDCA has smaller, earlier-phase trials. Neither rivals weight loss (5–10% body weight) for histologic resolution, which remains the standard-of-care intervention. Supplements are an adjunct, not a primary strategy.

Cholestasis — TUDCA's home turf

If liver labs show an isolated alkaline phosphatase or GGT elevation, or a cholestatic pattern, that is bile-acid territory and UDCA (prescription) is the right answer rather than over-the-counter TUDCA — but the underlying biology favours TUDCA over NAC in this scenario. PBC, intrahepatic cholestasis of pregnancy, and select drug-induced cholestasis are typical contexts.

Practical rule. The two supplements answer different questions. If your liver labs show a cholestatic pattern (high ALP/GGT, normal or modestly elevated ALT/AST), the relevant drug class is bile acids — see a hepatologist; TUDCA is the supplement-grade analogue. If your labs show a hepatocellular pattern (high ALT/AST, normal ALP), NAC is the supplement that has the most relevant mechanism. Most people don't need either — most cases of "I want to support my liver" are answered better by losing 7% body weight and stopping daily alcohol.

Dose, form, and timing

TUDCA: 500–1000 mg/day in divided doses, with or after meals. Taste is bitter; capsules are the realistic form. There is no validated optimal duration outside disease-specific contexts.

NAC: 600–1200 mg/day divided. Has a sulfur odour. Some users report GI upset; take with food. Effervescent and granulated forms exist for users sensitive to capsule sulfur smell.

Safety and interactions

TUDCA: Generally well-tolerated. Diarrhoea is the most common side effect at higher doses. Not for patients with biliary obstruction (cholelithiasis with blocked duct). Pregnancy/lactation: limited data; UDCA is used in intrahepatic cholestasis of pregnancy under specialist guidance.

NAC: GI upset, headache, rare hypersensitivity (more common with IV). FDA briefly questioned its OTC status (2020–2022) but reversed; sold widely. Caution with nitroglycerin (potentiates hypotension). Theoretical caution in asthma at very high doses (bronchospasm reports with inhaled NAC).

Can you stack them?

Mechanistically yes — they hit different targets. Stack rationale is strongest in NAFLD with mixed liver labs and in users with ongoing hepatic stressors. There is no large trial of the combination; mostly small mechanism-driven series.

Who should pick each

Pick TUDCA if: you have a cholestatic pattern on liver labs, your hepatologist is considering UDCA but you want a similar OTC starting point while seeking care, or you are working through the (controversial) "liver shield" use case for oral-androgen exposure (and have read the genuine warning that the right move is not using them).

Pick NAC if: you have NAFLD with elevated ALT, you want glutathione support broadly, you are an occasional moderate drinker looking for an evidence-graded antioxidant, or you have known acetaminophen exposure risk.

What we'd actually take

For most adults with a mild hepatocellular pattern and the usual NAFLD context: lose 5–10% body weight, stop daily alcohol, then layer NAC 600 mg b.i.d. for a 3–6 month trial with repeat ALT. For a cholestatic pattern: see a hepatologist before reaching for any supplement; TUDCA is not a substitute for diagnosis.

Sources

Read more: